

USSN: 10/748,524  
Attorney Docket: I-1995.184 US D1  
Response to Office Action of October 17, 2005

Amendments to the Claims:

1. (Currently amended) A multicomponent vaccine for cattle comprising an immunogenically effective combination of a protective antigen component from at least six clostridial organisms, a protective antigen component from at least one non-clostridial organism, which is *Moraxella Bovis* (*M. Bovis*) and ~~an~~ at least one adjuvant selected from the group consisting of oil -in- water, water-in-oil, Al (OH)<sub>3</sub>, Al<sub>2</sub>(SO<sub>4</sub>)<sub>3</sub>, Al PO<sub>4</sub>, bacterial extracts, a plant extract, a polymer and a liposome, wherein the vaccine is in a low dose volume of about 2 ml or less.
2. (Currently amended) A multicomponent vaccine for cattle, comprising an immunogenically effective combination of protective antigen components from at least seven clostridial organisms, a protective antigen component from at least one non-clostridial organism, which is *M. Bovis*, and ~~an~~ at least one adjuvant selected from the group consisting of oil -in- water, water-in-oil, Al (OH)<sub>3</sub>, Al<sub>2</sub>(SO<sub>4</sub>)<sub>3</sub>, Al PO<sub>4</sub>, bacterial extracts, a plant extract, a polymer and a liposome, wherein the vaccine is in a low dose volume of about 2 ml or less.

USSN: 10/748,524  
Attorney Docket: I-1995.184 US D1  
Response to Office Action of October 17, 2005

3. (Currently amended) The vaccine according to Claim 1, wherein the clostridial organism is selected from the group consisting of *Clostridium chauvoei*, *Clostridium septicum*, *Clostridium novyi*, *Clostridium perfringens* type C, *Clostridium perfringens* type D, *Clostridium sordellii*, *Clostridium haemolyticum* *haemolyticum* and *Clostridium tetani*.

Claims 4-14 Cancelled

15. (Previously presented) The vaccine according to Claim 3, wherein the 6 clostridial organisms are selected from the group consisting of *Cl. chauvoei*, *Cl. septicum*, *Cl. novyi*, *Cl. perfringens* type C, *Cl. perfringens* type D, *Cl. haemolyticum* and *Cl. sordellii*.

16. (Cancelled)

17. (Previously presented) The vaccine according to Claim 2, wherein the 7 clostridial organisms are selected from the group consisting of *Cl. chauvoei*, *Cl. septicum*, *Cl. novyi*, *Cl. perfringens* type C, *Cl. perfringens* type D, *Cl. sordellii*, *Cl. haemolyticum*, and *Cl. tetani*.

USSN: 10/748,524  
Attorney Docket: I-1995.184 US D1  
Response to Office Action of October 17, 2005

18. (Previously presented) The vaccine according to Claim 1, wherein the protective antigen component from 6 clostridial organisms is from *Cl. chauvoei*, *Cl. septicum*, *Cl novyi*, *Cl. perfringens* type C, *Cl. perfringens*, type D, and *Cl. sordellii*.
19. (Previously presented) The vaccine according to claim 2, wherein the protective antigen component from 7 clostridial organisms is from *Cl. chauvoei*, *Cl. septicum*, *Cl novyi*, *Cl. perfringens* type C, *Cl. perfringens*, type D, *Cl. haemolyticum* and *Cl. sordellii*.

Claims 20-39 Canceled

40. (Currently amended) The vaccine according to claim 2, wherein the 7 clostridial organisms are *Cl. chauvoei*, *Cl. septicum*, *Cl novyi*, *Cl. perfringens* type C, *Cl. perfringens* type D, *Cl. sordellii* and *Cl. haemolyticum* and the protective antigen component from at least one non-clostridial organism comprises *H. Haemophilus somnis* and *M. bovis*.

Claims 41-45 (Canceled)

USSN: 10/748,524  
Attorney Docket: I-1995.184 US D1  
Response to Office Action of October 17, 2005

46. (Previously presented) A method of immunizing an animal comprising administering an effective amount of the vaccine of Claim 1.

47. (Previously presented) A method of immunizing an animal comprising administering an effective amount of the vaccine of Claim 2.